78 related articles for article (PubMed ID: 10452316)
1. Role of FDG PET in metastatic thyroid cancer.
Wong CO; Dworkin HJ
J Nucl Med; 1999 Jun; 40(6):993-4. PubMed ID: 10452316
[No Abstract] [Full Text] [Related]
2. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
3. Extensive lymph node metastases found by (18)F-FDG-PET/CT in a patient with diffuse sclerosing variant of papillary thyroid carcinoma.
Xu YH; Song HJ; Qiu ZL; Luo QY
Hell J Nucl Med; 2011; 14(2):188-9. PubMed ID: 21761030
[No Abstract] [Full Text] [Related]
4. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
5. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
6. [PET-FDG in thyroid cancer with high thyroglobulin levels and negative 131-I scan. A case report].
Ortega F; Maldonado A; Marañes P; Montz R; Pérez-Castejón MJ; Melgarejo M; Ruiz JA; Carreras JL
Rev Esp Med Nucl; 1999; 18(1):50-4. PubMed ID: 10074219
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
Laking GR; Price PM
J Nucl Med; 2002 Dec; 43(12):1728-9; author reply 1729. PubMed ID: 12468527
[No Abstract] [Full Text] [Related]
8. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
Kim SJ; Lee TH; Kim IJ; Kim YK
Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
[TBL] [Abstract][Full Text] [Related]
9. FDG PET and alternative imaging in the management of thyroid carcinoma.
Al-Nahhas AM
Nucl Med Rev Cent East Eur; 2003; 6(2):139-45. PubMed ID: 14737730
[TBL] [Abstract][Full Text] [Related]
10. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
[TBL] [Abstract][Full Text] [Related]
11. Follow-up in patients with differentiated thyroid carcinoma with positive 18F-fluoro-2-deoxy-D-glucose-positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I posttreatment whole body scans.
van Tol KM; Jager PL; Dullaart RP; Links TP
J Clin Endocrinol Metab; 2000 May; 85(5):2082-3. PubMed ID: 10843201
[No Abstract] [Full Text] [Related]
12. Role of PET scan in management of oesophageal cancer.
Pramesh CS; Mistry RC
Eur J Surg Oncol; 2005 May; 31(4):449. PubMed ID: 15837055
[No Abstract] [Full Text] [Related]
13. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels].
Mariscal Labrador E; García Burillo A; Castell-Conesa J; Obiols Alfonso G; Kisiel González N; Barios Profitós M; Aguadé-Bruix S; Mesa Manteca J
Rev Esp Med Nucl Imagen Mol; 2013; 32(3):146-51. PubMed ID: 22726673
[TBL] [Abstract][Full Text] [Related]
14. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
15. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
16. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S105-9. PubMed ID: 12739343
[No Abstract] [Full Text] [Related]
17. A new look at breast cancer.
Wagner HN
J Nucl Med; 1999 Jun; 40(6):1009-10. PubMed ID: 10452319
[No Abstract] [Full Text] [Related]
18. FDG positron emission tomography detection of pelvic nodal metastases in gynecologic cancer.
Siegel BA; Adler LP; Wahl RL
AJR Am J Roentgenol; 2002 Mar; 178(3):762-4. PubMed ID: 11856715
[No Abstract] [Full Text] [Related]
19. Comparison of F-18 FDG to I-123 and I-131 scans in thyroid carcinoma.
Bakheet SM; Powe JE; Hammami MM; Ahmed M
Clin Nucl Med; 1997 Jun; 22(6):438-9. PubMed ID: 9193832
[No Abstract] [Full Text] [Related]
20. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography.
Akkas BE; Demirel BB; Vural GU
Thyroid; 2014 Feb; 24(2):287-95. PubMed ID: 23750862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
